Background. After the implementation of a population-based programme of chest x-ray (CXR) screening on smokers in Varese, Italy, lung cancer (LC) mortality was significantly reduced. Analysis of the incremental costs due to this type of screening programme is needed to evaluate its economic impact on the healthcare system.
Methods. In July 1997 a population-based cohort, consisting of all high-risk smokers (n=5,815) identified among 60,000 adult residents from the Varese province, was invited to a LC screening programme (an annual CXR for five years) in a general practice setting, and was observed through 2006. Invitees received National Health Service (NHS) usual care, with the addition of CXRs in screening participants. At the end of observation, among the 245 LCs diagnosed in the entire screening-invited cohort the observed LC deaths were 38 fewer than expected. To estimate the incremental direct cost due to screening in the invited cohort for the period July 1997-2006, we compared the direct cost of screening administration, CXR screens and LC management in the invited cohort and in the uninvited and unscreened controls in NHS usual care setting.
Results. Over the 9.5 years, the total incremental direct healthcare costs (including screening organization/administration, CXR screens, additional procedures prompted by false-positive tests, overdiagnosed LCs) were estimated to range from € 607,440 to € 618,370 (in euros as of 2012), equating to between € 15,985-€ 16,273 per patient out of the 38 LC deaths averted.
Conclusions. In a general practice setting, the incremental cost for a CXR screening programme targeted at all high-risk smokers in a population of 60,000 adults was estimated to be about € 65,000 per annum, approx. € 16,000 for each LC death averted. Monaldi Arch Chest Dis 2013; 79: 2, 67-72. many lives, especially given the high incidence of LC worldwide and the potentially wide applicability of CXR screening. In order to explore the NHS budget impact of a population-based LC screening intervention, it is necessary to evaluate the direct costs involved, the benefits as well as the harms. Here we describe the economic evaluation of the annual CXR screening programme we carried out in the Varese province in a general practice setting.
Methods
We aimed to evaluate the incremental costs attributable to the programme of CXR screening for LC which we performed from July 1997 through December 2006. To this effect, over the 9.5-year duration of the screening programme we analyzed the total direct costs of CXR screening and LC management in the screening-invited cohort, and compared it with the total direct cost of LC management in a control group of patients observed in the general population of the same area in the absence of screening.
Throughout this paper the values of healthcare services, procedures and interventions were reported in Euros as of the year 2002, the central year of our screening study (tables 1-3). These values were estimated based on the 2002 Tariff of Lombardy Regional Bulletin and on data provided by the Oncology, Radiotherapy and Palliative Care Units at the Varese Ospedale di Circolo. For a more direct comparison with the most recently published literature, the incremental costs incurred with screening were expressed in terms of Euros as of 2012.
Cost of the screening programme
Computation of direct costs attributable to the screening programme included: a) the cost of organization and administration; b) the cost of CXR screenings; c) the cost of additional procedures prompted by false-positive tests. Moreover, we considered the direct cost of overdiagnosed LCs, which was based on the estimate that in the Mayo Lung Project approximately 5% of screen-detected LCs were overdiagnosed [3] .
Cost of LC management on the screening-invited cohort
For each of the 245 LC cases that were diagnosed overall in the cohort [1] , we computed all healthcare costs for LC management, from the time of diagnosis until the time of death. For subjects still alive at the end of study, the computation of costs was truncated at the study cut off, on December 31, 2006. Briefly, to calculate the total cost of each LC case in the cohort, costs related to LC diagnosis, staging, treatment and follow-up procedures (tables 1-3) that were individually incurred were included, stratified by stage, histology (non-small cell lung cancer, small cell lung cancer) and treatment (surgery, chemotherapy, radiation). To determine the price of the component services, we considered the phase of care and the frequency of cost-generating follow-up procedures for each case. For components with little variability of cost in the various different NHS facilities throughout the Varese province, the average cost was indicated; if the overall cost was considerably variable, the lowest value and the highest value were taken (tables 1-3).
Cost of LC management in the control group
As a control group we used a previously described group of 156 uninvited and unscreened LC patients diagnosed during the 2000 calendar year in the Varese district area, who possessed the necessary screening criteria [1] . Over the 9.5-year timeframe we computed the total direct cost of healthcare procedures and interventions (tables 1-3) incurred for LC management for these 156 control group patients, who received the NHS usual standard of care in the absence of screening.
Results

Cost of the screening programme
The total direct cost of the screening programme over the 9.5-year period from July 1997 through December 2006 was estimated to range from € 390,934 to € 394,042 (table 4), after adding up the cost components a), b), c), as follows:
a) Organization and administration
The general expenses incurred for the initial organization of the screening programme comprised: office supplies; printed recruitment forms and brochures; mailing of screening invitation letters; advertising of screening with posters and announcements in local newspapers, radio and TV; purchase of personal computers to store CXR readings in the 7 NHS radiologic centers collaborating in the project; dedicated software for database in the project main office. Cost of programme administration included: part-time secretary; office utilities and material supplies; staff meetings. Total cost of organization and administration over the 9.5 years was € 242,632. 
b) CXR screens
Total expenditure for the 5,581 screening tests performed on the screening participants (baseline, n=1,244; annual screens, n=4,337) was € 86,450.
c) Additional procedures prompted by screening
Uncertain or false-positive tests [1] prompted the following additional investigations: 190 chest computed tomography (CT) exams with contrast; one fine-needle aspirate cytology of lung; 8 thoracoscopic lung wedge resections for biopsy. The total cost of these additional procedures, none of which caused severe complications, ranged from € 61,852 to € 64,960.
Cost of LC management in the screening-invited cohort
The total direct cost incurred for healthcare of all LC cases diagnosed in participants and in nonparticipants of the invited cohort is shown in table 5, with the indication of the lowest and highest value of services. The total direct cost of all 245 LC cases of the screening-invited cohort ranged from € 2,959,155 to € 3,324,662 (table 5). The latter cost will subsequently be compared in table 5 with the total direct cost of only 243 LCs of the control group, as 2 LCs in the invited cohort were likely to have been overdiagnosed (see below).
Overdiagnosed LCs
As 34 LCs were screen-detected in our screening programme [1] , we approximated that 2 LCs (5%) had been overdiagnosed. Accordingly during the calculation of the incremental costs of screening, to account for overdiagnosed LCs, the total direct cost of only 243 control group LCs will be subtracted from the cost of the 245 LCs from the screening-invited cohort (see calculation in table 5).
Total cost of screening and LC management in the screening-invited cohort
The cost of the screening programme added to the cost of LC management of all 245 cases in the screening-invited cohort totaled between € 3,350,089 and € 3,718,704 (computation shown in table 5).
Cost of LC management in the control group
The mean direct cost of LC management for each patient of the control group was estimated to range from € 11,809 to € 13,361, implying a total expenditure ranging from € 2,869,615 to € 3,246,723 for the 243 LCs from the control group (table 5) . The total cost of LC management was slightly lower in the control group compared to the invited cohort, as in the latter there were 2 overdiagnosed cases treated and higher number of stage I surgically treated patients (table 5) .
Incremental costs of LC management including screening
In the invited cohort the cumulative incremental costs of LC management, including screening, was estimated to range between € 471,981 and € 480,474 over the 9.5-year study period (see calcu- Table 5 Cost was calculated for 243 cases because 2 cases were estimated to be overdiagnosed (see text). # Cost of administration, CXRs and false-positives management. @ A total of 38 LC deaths were averted during the 9.5 years of study. lation in table 5). After conversion based on the IS-TAT healthcare price index, this corresponds to a total of between € 607,440 and € 618,370 as of 2012 (approx. € 63,941 -€ 65,092 per annum). Accordingly, the incremental costs of LC management including screening ranged between € 15,985 and € 16,273 for each of the 38 LC deaths averted in the cohort.
In conclusion, in a general population of 60,000 adults we carried out an annual CXR screening program targeted at 5,815 high-risk smokers, and found that the overall healthcare expense for LC management including screening increased approximately by € 65,000 per annum.
Discussion
It has long been recognized that LC has better prognosis when it is incidentally detected during routine CXR examinations. LCs when incidentally diagnosed are frequently at an early stage and are resectable, meanwhile symptom-detected cases are predominantly advanced stage cases and are rarely curable [4] [5] [6] . For this reason chest radiograph, a widely accessible and relatively inexpensive examination, is intuitively appealing as a screening tool for early stage LC diagnosis in subjects with an increased risk of death from LC such as smokers and former smokers. However, the numerous randomized trials carried out to evaluate CXR screening for LC have brought only mixed results [7] [8] [9] [10] and present important methodological weaknesses [2, 5, 7, 9, 11] . All of the randomized trials have been criticized due to a self-selection bias of volunteers [7, 12] , and there still remains uncertainty regarding the value of LC screening at population level in the real world [2] . Accordingly the U.S. Preventive Services Task Force stated that the evidence provided, whether it be for or against CXR screening, is insufficient [13] .
Nevertheless, several authors have set out to develop LC screening programs and cost-effectiveness models with sensitivity analyses [6, 14, 15] . These analyses are quite difficult to interpret. Models of simulated cohorts have provided highly variable estimates, ranging from highly cost-effective to non cost-effective treatment methods [14] [15] [16] [17] , and it remains uncertain whether a public healthcare system can afford the financial burden of population-based screening for LC.
In 1997 we started a population-based programme consisting of annual CXR screenings in the cohort of high-risk smokers who were identified within a general population of 60,000 adults from the Varese province. After the 9.5 year observation period we subsequently reported that within the screening-invited cohort, LC mortality had reduced by 18% [2] . At this point we analyzed the direct costs of our screening programme. For the entire cohort of 5,815 screening-invited smokers (21% of whom participated) [12] , the incremental cost (as of 2012) of LC management including screening was estimated to range between € 607,440 and 618,370 (approximately € 65,000 per annum). As 38 fewer LC deaths were recorded in the invited cohort, the additional cost of screening to avoid one LC death (when compared with no screening and after accounting for overdiagnosis) was approximately € 16,000. The latter cost favourably compares with the recently estimated $240,000 additional cost of screening with CT to avert one LC death [6] , a ten-fold cost increase. Our study has limitations. First of all, cost estimates calculated in 2002 were applied to the whole period from July 1997 through December 2006. Because 2002 was the central year of our programme, it is highly unlikely that the overall cost of healthcare for all LCs in the study was markedly either under-or overestimated. Secondly, an element of cost was waived in our analysis, possibly causing screening program costs to be slightly underestimated: the screening programme main office was made available free of charge on NHS premises at the Center for Thoracic Surgery of University of Insubria, at the Varese Ospedale di Circolo. A strong feature of this study is the analytical computation based on all costs actually incurred during screening and LC management in all individual cases which occurred both within the invited cohort and the control group in the NHS setting in Varese. With emphasis of the current study being on cost, a complete cost-effectiveness assessment of the screening programme carried out on smokers remains to be done. However, the quantification of all the direct costs we incurred during our population-based CXR screening programme may be used by health policy makers to better explore the NHS budget impact and economic sustainability of LC screening.
